Literature DB >> 16428330

Analysis on the molecular species and concentration of circulating ADAMTS13 in Blood.

Kenji Soejima1, Hitomi Nakamura, Masaki Hirashima, Wataru Morikawa, Chikateru Nozaki, Tomohiro Nakagaki.   

Abstract

ADAMTS13 is the metalloprotease responsible for the proteolytic degradation of von Willebrand factor (VWF). A severe deficiency of this VWF-cleaving protease activity causes thrombotic thrombocytopenic purpura. This protease, comprising 1,427 amino acid residues, is composed of multiple domains, i.e., a preproregion, a metalloprotease domain, a disintegrin-like domain, a thrombospondin type-1 motif (Tsp1), a cysteine-rich domain, a spacer domain, seven Tsp1 repeats, and two CUB domains. We prepared one polyclonal and seven monoclonal antibodies recognizing distinct epitopes spanning the entire ADAMTS13 molecule. Of these antibodies, two of the monoclonal ones, which recognize the disintegrin-like and cysteine-rich/spacer domains, respectively, abolished the hydrolytic activity of ADAMTS13 toward both a synthetic substrate, FRETS-VWF73, and the natural substrate, VWF. In addition, these antibodies blocked the binding of ADAMTS13 to VWF. These results revealed that the region between the disintegrin-like and cysteine-rich/spacer domains interacts with VWF. Employing these established polyclonal and monoclonal antibodies, we examined the molecular species of ADAMTS13 circulating in the blood by immunoprecipitation followed by Western blot analysis, and estimated the plasma concentration of ADAMTS13 by enzyme-linked immunosorbent assay. These studies indicated that the major fraction of ADAMTS13 in blood plasma consisted of the full-length form. The concentration of ADAMTS13 in normal plasma was approximately 0.5-1 microg/ml.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16428330     DOI: 10.1093/jb/mvj013

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  20 in total

1.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

2.  Localization of blood proteins thrombospondin1 and ADAMTS13 to cerebral corpora amylacea.

Authors:  He Meng; Xiaojie Zhang; Mila Blaivas; Michael M Wang
Journal:  Neuropathology       Date:  2009-04-28       Impact factor: 1.906

3.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

4.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.

Authors:  Eric M Ostertag; Khalil Bdeir; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; Lenka Yunk; Vincent M Hayes; David G Motto; Mortimer Poncz; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

5.  Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13.

Authors:  L Deforche; E Roose; A Vandenbulcke; N Vandeputte; H B Feys; T A Springer; L Z Mi; J Muia; J E Sadler; K Soejima; H Rottensteiner; H Deckmyn; S F De Meyer; K Vanhoorelbeke
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

6.  The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages.

Authors:  Fabian C Verbij; Nicoletta Sorvillo; Paul H P Kaijen; Johana Hrdinova; Ivan Peyron; Rob Fijnheer; Anja Ten Brinke; Alexander B Meijer; Floris P J van Alphen; Timo K van den Berg; Jonas J H Graversen; Soren K Moestrup; Jan Voorberg
Journal:  Blood Adv       Date:  2017-01-16

7.  Role of calcium in regulating the intra- and extracellular cleavage of von Willebrand factor by the protease ADAMTS13.

Authors:  Shobhit Gogia; Anju Kelkar; Changjie Zhang; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood Adv       Date:  2017-10-20

8.  Cyclosporin A impairs the secretion and activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeat).

Authors:  Klilah Hershko; Vijaya L Simhadri; Adam Blaisdell; Ryan C Hunt; Jordan Newell; Sandra C Tseng; Alon Y Hershko; Jae Won Choi; Zuben E Sauna; Andrew Wu; Richard J Bram; Anton A Komar; Chava Kimchi-Sarfaty
Journal:  J Biol Chem       Date:  2012-11-09       Impact factor: 5.157

Review 9.  Pathogenesis of thrombotic microangiopathies.

Authors:  X Long Zheng; J Evan Sadler
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

10.  Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Authors:  Zuben E Sauna; Chinyere Okunji; Ryan C Hunt; Tanvi Gupta; Courtni E Allen; Elizabeth Plum; Adam Blaisdell; Vahan Grigoryan; S Geetha; Robert Fathke; Kenji Soejima; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.